Navigation Links
Elsevier's PharmaPendium(TM) Adds European Medicines Agency (EMEA) Documents
Date:10/14/2008

NEW YORK, October 14 /PRNewswire-FirstCall/ --

- Site Becomes the Only Source of Consolidated, Searchable Access to Both FDA and EMEA Drug Approval Documents

PharmaPendium ( http://www.info.pharmapendium.com/ ), Elsevier's online resource for authoritative drug safety data, has significantly expanded its content offering with a new release containing the European Medicines Agency's (EMEA) European Public Assessment Reports (EPARs). The addition of this content makes PharmaPendium the only source of consolidated, searchable access to US Food and Drug Administration (FDA) and EMEA drug approval documents on a single site, with a single search.

EMEA is the European agency for the evaluation of medicinal products. This new content offers critical insights into the EMEA regulatory point of view, their reasoning underlying drug approval and the qualifications put on that approval.

"The Pharmaceutical industry is facing increasing pressure to identify drug candidates with the best possible safety, delivery and efficacy profiles as early as possible and PharmaPendium is uniquely positioned to address these challenges," commented Philip MacLaughlin, Senior Product Manager at Elsevier.

The EMEA's EPAR documents cover medicines assessed by the Committee for Medicinal Products for Human Use (CHMP). EPAR documents include efficacy, indication, safety and pharmacokinetics data and mode of action information. The EMEA database on PharmaPendium makes readily accessible approximately 80,000 pages of searchable documents for more than 300 active ingredients approved for the European market - some not approved in the US. It also presents preclinical and clinical toxicity and adverse effects data manually extracted from these documents. General product information documents are also included.

"Providing our users with the European Medicines Agency documents adds another important dimension to our coverage," said MacLaughlin. "This information will benefit companies operating globally because it provides critical access to another major regulatory body's points of view, precedents and data, including drugs approved only in Europe, and the availability of this information, combined with the FDA documents and other PharmaPendium data sources, will lead to a deeper understanding of the full scope of projected risks early in the drug development process and consequently reduce drug development costs and avoid regulatory cycling."

The EMEA Documents database is included as part of PharmaPendium licensing agreements at no additional fee and the content is automatically available to all users. More information about the European Medicines Agency and EMEA approval documents can be found at http://www.info.pharmapendium.com/emea.

About PharmaPendium(TM)

PharmaPendium (http://www.info.pharmapendium.com), The Essential Resource for Preclinical Safety and Risk Assessment, is a unique online resource that provides access via a single point to searchable and trusted drug information. It covers over 3100 approved drugs, with integrated preclinical, clinical and post-marketing safety data.

PharmaPendium is designed to meet the needs of preclinical safety assessment teams, toxicologists, pharmacokineticists, safety pharmacologists, regulatory affairs staff, pharmacoepidemiologists, clinical researchers and information specialists. It enables text-search of FDA Approval Packages and European Medicines Agency (EMEA) European Public Assessment Reports (EPAR) Approval Documents as well as other data sources. Adverse events and toxicity data are carefully extracted from preclinical and clinical studies from all of these sources. Elsevier offers a broad spectrum of solutions to make processes in drug discovery, preclinical and clinical drug development more efficient, e.g. CrossFire and Reaxys, EMBASE and PharmaPendium. More information can be found at http://www.elsevierforindustry.com.

About Elsevier

Elsevier is a world-leading publisher of scientific, technical and medical information products and services. Working in partnership with the global science and health communities, Elsevier's 7,000 employees in over 70 offices worldwide publish more than 2,000 journals and 1,900 new books per year, in addition to offering a suite of innovative electronic products, such as ScienceDirect (http://www.sciencedirect.com/), MD Consult ( http://www.mdconsult.com/), Scopus (http://www.info.scopus.com/), bibliographic databases, and online reference works.

Elsevier (http://www.elsevier.com/) is a global business headquartered in Amsterdam, The Netherlands and has offices worldwide. Elsevier is part of Reed Elsevier Group plc (http://www.reedelsevier.com/), a world-leading publisher and information provider. Operating in the science and medical, legal, education and business-to-business sectors, Reed Elsevier provides high-quality and flexible information solutions to users, with increasing emphasis on the Internet as a means of delivery. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
PharmaPendium is a trademark of Elsevier B.V.

Contact:

Tom Reller,

Director of Corporate Relations,

Phone: +1-212-462-1912,

E-mail: T.Reller@Elsevier.com .


'/>"/>
SOURCE Elsevier
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
2. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
3. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
4. Kline Study: Better Brushing Habits Boost European Oral Care Sales
5. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
6. European Centre for Modern Drug Discovery Established in Hamburg
7. SAFC Expands European Commercial Manufacturing and Storage Capacities With $10 Million Investment
8. Cardica Receives European CE Mark for C-Port Flex A System for Use in Coronary Artery Bypass Surgery
9. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
10. Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimers Vaccine in 19 Countries
11. Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Hodgkins Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... ... (TDR) procedures can be safely completed in an ambulatory surgery center (ASC) with ... (ACDF) procedures and previous two-year TDR studies. , Jake Lubinski, president of ...
(Date:2/24/2017)... , Feb. 24, 2017 Symic Bio, a ... a new category of therapeutics, announced today the completion ... in peripheral artery disease. The trial will evaluate the ... therapeutic, in the reduction of restenosis following angioplasty. ... development milestone for SB-030," said Nathan Bachtell , ...
(Date:2/24/2017)... Corporation (NASDAQ: VWR), the leading global independent provider of product ... its financial results for the fourth quarter and full year ... 4Q16 record quarterly net sales of $1.13 billion, up ... 4Q16 EMEA-APAC segment net sales increased ... net sales increased 2.5%, or down 0.9% on an organic ...
(Date:2/23/2017)... - The Fight Against Cancer Innovation Trust (FACIT) and ... to report that Fusion Pharmaceuticals Inc. (Fusion) has closed ... Innovation – JJDC, Inc. (JJDC) as the lead investor. ... Partners, and Genesys Capital, as well as founding investor ... ...
Breaking Biology Technology:
(Date:2/2/2017)... , Feb. 2, 2017  EyeLock LLC, a market ... new white paper " What You Should Know About ... of ensuring user authenticity is a growing concern. In ... of users. However, traditional authentication schemes such as username/password ... Biometric authentication offers an elegant solution to the ...
(Date:1/30/2017)... , Jan. 30, 2017   Invitae Corporation ... fastest growing genetic information companies, today announced that it ... results and provide 2017 guidance on Monday, February 13, ... call that day at 4:45 p.m. Eastern / 1:45 ... management team will briefly review financial results, guidance, and ...
(Date:1/24/2017)... , Jan. 24, 2017 Biopharm ... of the laboratory use of nuclear magnetic resonance ... experienced end-users and profiled current practices, developments, trends ... as well as growth and opportunities. These areas ... suppliers, NMR instruments, needs and innovation requirements, hyphenated ...
Breaking Biology News(10 mins):